Boca Raton, Florida — August 14, 2025 — Leads & Copy — Entero Therapeutics, Inc. (NASDAQ: ENTO) will implement a 1-for-3 reverse stock split of its common stock. Trading on a split-adjusted basis is expected to begin on the Nasdaq Capital Market on August 18, 2025.
The reverse stock split, approved by the Board of Directors and shareholders, aims to regain compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share.
The split will consolidate every 3 shares into one, reducing outstanding common stock from approximately 4.77 million to 1.59 million shares. Stockholders entitled to fractional shares will receive cash in lieu of those shares.
Interim CEO Richard Paolone stated the split is a necessary step to maintain the company’s Nasdaq listing and enhance shareholder value.
Entero Therapeutics, Inc. is focused on targeted, non-systemic therapies for gastrointestinal (GI) diseases, including Adrulipase for exocrine pancreatic insufficiency.
Richard Paolone, Interim Chief Executive Officer
Investor Contact: investors@enterothera.com
Source: Entero Therapeutics, Inc.
